Brazil’s health regulator, Anvisa, has ordered the suspension of multiple insulin, tirzepatide, and peptide products sold without proper authorisation, targeting unlicensed online sales and unregistered manufacturers amidst ongoing regulatory crackdowns.
Brazil’s health regulator has ordered the suspension of sales of several insulin, tirzepatide and peptide products that were being marketed without the authorisations required under national rules, in the latest move against medicines sold online with no clear regulatory trail. According to Anvisa, the action covers products distributed by Costa Mar Comércio Licitatório Ltda and a range of peptides offered through websites linked to unregistered or unidentified manufacturers.
The agency said all batches of insulin supplied by Costa Mar are covered by the ban after inspectors found the company lacked the operating authorisation needed to distribute medicines. A municipal health inspection in Petrópolis, in Rio de Janeiro state, also concluded that the business was not operating at the address it had registered and that no sanitary licence was displayed there, raising further doubts about its legitimacy.
Anvisa also moved against peptide products sold on peptideospro.com and peptideosdobrasil.com.br, saying they may neither be sold, manufactured, distributed, advertised, transported nor used. Items named in the order include BPC157 & TB500 40 mg, NAD+ 1000 mg, Tirzegen 60 mg Tirzepatida, Retagen 40 mg Retatrutide and Glow GHK-CU 70 mg. Some of the products were attributed to companies such as Alluvi Healthcare, Synedica Labs and Oxygen Pharm, while others were described as coming from an unknown producer.
The measure was published in Resolution 3,947/2026 in Brazil’s Official Federal Gazette. It follows a series of similar enforcement actions by Anvisa this year, including earlier restrictions on irregular tirzepatide products and so-called slimming pens sold without registration. In September, the regulator also warned about powdered tirzepatide being promoted online, stressing that medicines handled outside sterile conditions can carry serious contamination risks.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
